GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
32.69
+0.61 (1.89%)
GSK Plc is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer
The company specializes in the research, development, and manufacturing of a wide range of pharmaceuticals, vaccines, and consumer health products. GSK's portfolio covers various therapeutic areas, including respiratory diseases, HIV, oncology, immunology, and infectious diseases, with a strong emphasis on innovation and scientific advancement. Committed to addressing health challenges, GSK collaborates with various partners and stakeholders to deliver accessible healthcare solutions that meet the needs of patients and communities around the world.
CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following the U.S.'s first human death from H5N1 bird flu.
FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk. Study estimates 7-9 excess GBS cases per million doses.
The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus. The CDC is also reporting high levels of acute respiratory illnesses nationwide.
Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in Phase 2. Data expected in 2025.
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.
Lawyer files petition against polio vaccine, part of broader anti-vaccine campaign by Robert F. Kennedy Jr. and Aaron Siri, causing concerns for vaccine policies and pharma companies. Trump considering removing some vaccines for children.
An analysis of NICE-approved drugs from 2000–2020 reveals trade-offs in NHS resource allocation, with high costs leading to a net loss of population health gains.
Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.
Bird flu has been detected in a batch of raw milk sold in California and a voluntary recall of the milk has been issued at the request of the state's department of public health.
